Ara-290 16mg
Ara-290 is an EPO-derived peptide targeting the innate repair receptor for neuroprotection, tissue repair, and neuropathic pain research.
Mechanism
Ara-290 selectively triggers the heterodimeric innate repair receptor (EPOR/CD131) to initiate anti-inflammatory and tissue-protective signaling cascades without activating erythropoiesis.
Dosing
Standard laboratory protocols report an initial subcutaneous dose of 4 mg administered once daily.
Reconstitution
Reconstituting a 16 mg vial with 2.0 mL of bacteriostatic water results in a final research concentration of 8 mg/mL.
Storage
Keep lyophilized vials stored at -20°C and maintain reconstituted solutions at 2–8°C protected from light without refreezing.
Mix & measure Ara-290 16mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure Ara-290 16mg
Vial strength → BAC water → target dose
Total doses in vial: 4.0
U-100 syringe: 100 units = 1 mL
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Weeks 1–4 | 4 mg once daily (SC) | 50 units (0.50 mL) |
| Weeks 5–12 (optional extension) | 4 mg once daily (SC) | 50 units (0.50 mL) |
| Advanced / Aggressive (Weeks 1–4) | 8 mg once daily (SC) | 100 units (1.00 mL) |
Reconstitution Steps
- 1
Aspirate 2.0 mL of bacteriostatic water using a sterile syringe.
- 2
Slowly introduce the diluent against the inner glass wall of the vial to minimize foaming.
- 3
Gently roll or swirl the vial until the lyophilized powder dissolves completely, avoiding shaking.
- 4
Record the date and concentration on the vial label.
- 5
Store the reconstituted solution in a refrigerator at 2–8°C away from light.
Supplies Needed
Peptide Vial
Ara-290 16 mg lyophilized powder supply for research reconstitutions.
Insulin Syringes (U-100)
Sterile 1 mL syringes utilized for precise measurement and subcutaneous administration.
Bacteriostatic Water
Preserved sterile diluent required to reconstitute the peptide solution.
Alcohol Swabs
Antiseptic wipes used to clean vial stoppers and prospective injection areas.
Why researchers study it
Neuropathic pain alleviation
Tissue protection via innate repair signaling
Small-fiber and corneal nerve regeneration
Mitigation of diabetic neuropathy and tissue complications
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
Ara-290, also known as cibinetide, is an engineered 11-amino-acid synthetic peptide modeled after the helix-B domain of erythropoietin. Unlike endogenous erythropoietin, it does not induce hematopoiesis or elevate red blood cell counts, thereby eliminating risks associated with polycythemia and thrombotic complications. Instead, it selectively engages pathways that facilitate cellular repair and moderate localized inflammatory responses. In investigative clinical and pre-clinical settings, Ara-290 is primarily assessed for its potential neuroregenerative and cytoprotective properties. Much of the clinical interest focuses on peripheral neuropathies, including small-fiber neuropathy linked with systemic conditions such as sarcoidosis and type 2 diabetes. Trial metrics have historically monitored changes in pain perception, quality of life markers, and structural indicators such as corneal nerve fiber density. While Ara-290 achieved Phase 2 evaluation and gained orphan drug designation for specific rare conditions, it remains strictly an unapproved, investigational compound. Experimental handling must strictly observe laboratory-grade standards to assess tissue healing without systemic hematopoietic interference.
References
- 1.Molecular Medicine, 2011 — ARA 290, a peptide derived from the helix-B of erythropoietin, that selectively activates the innate repair receptor
- 2.Journal of Diabetes Science and Technology, 2013 — Phase 2 study of cibinetide (ARA 290) 4 mg/day subcutaneously in patients with diabetic neuropathic pain
- 3.Molecular Medicine, 2014 — Randomized dose-ranging trial of cibinetide (1, 4 and 8 mg daily for 28 days) in sarcoidosis small-fiber neuropathy
- 4.Journal of Internal Medicine, 2015 — Cibinetide improves small-fiber neuropathy symptoms and corneal nerve-fiber measures in early clinical studies
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allSS-31 10mg
Mitochondria-targeted synthetic tetrapeptide researched for cardiolipin stabilization, ATP production, and cellular aging models.
View ProtocolLipo-C 1250mg (10 mL)
A pre-mixed lipotropic solution pairing methionine, inositol, choline, and vitamin B12 to investigate hepatic lipid clearance and energy pathways.
View ProtocolPramlintide 5mg
Synthetic amylin analogue evaluated in metabolic models for delayed gastric emptying, postprandial glucose stability, and satiety.
View Protocol